Nazli Dizman(@NazliDizman) 's Twitter Profileg
Nazli Dizman

@NazliDizman

MD & Researcher | Heme/Onc fellow @MDAndersonNews | @YaleIMed ‘23 | Postdoc @cityofhope @montypal | @ASCOTECAG | #WomenInMedicine | T/RT my own

ID:733782620958511105

linkhttps://coi.asco.org/share/J7C-BSUP/Nazli%20Dizman calendar_today20-05-2016 22:13:04

17,1K Tweets

8,2K Followers

5,6K Following

Follow People
Evan Hall(@EvanHallMD) 's Twitter Profile Photo

Inspiring talk from Fred Hutchinson Cancer Center survivorship team member and melanoma survivor Barb Regis on importance of survivorship definition, thriving after surviving, integrating care with PCPs, and much more. Speaking at NW Melanoma Symposium Melanoma Research Foundation

Inspiring talk from @fredhutch survivorship team member and melanoma survivor Barb Regis on importance of survivorship definition, thriving after surviving, integrating care with PCPs, and much more. Speaking at NW Melanoma Symposium @CureMelanoma
account_circle
Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo

The evidence is here. The Lancet comprehensive study ranks “Air Pollution” as the leading contributor for global disease burden. Our friend Charles Swanton The Crick has established the link between air pollution and Cancer risk ! Watch his ESMO - Eur. Oncology talks/read his nature papers!

account_circle
MD Anderson Cancer Center(@MDAndersonNews) 's Twitter Profile Photo

“Rather than telling the patient to come every day for five days for an IV chemotherapy treatment, we can just prescribe a pill they can take at home,” says our Dr. Nitin Jain.

Learn about it here: brnw.ch/21wJVqo Nitin Jain Tapan Kadia Hima Atluri, MD

account_circle
Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation(@RManochakian) 's Twitter Profile Photo

🚨🔥OncoAlert Hot off the Press.

New by ASCO & @IntegrativeOnc on:

“Management of -related during & after cancer treatment.”

is a very common & distressing symptom in with .
We CAN HELP them.

👇🏼
brnw.ch/21wJRao

🚨🔥@OncoAlert Hot off the Press. New #Guidelines by @ASCO & @IntegrativeOnc on: “Management of #Cancer-related #Fatigue during & after cancer treatment.” #Fatigue is a very common & distressing symptom in #Patients with #Cancer. We CAN HELP them. 👇🏼 brnw.ch/21wJRao
account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

The OncoAlert 🚨COMPLETE COVERAGE of 🇩🇪is COMING

✉️REGISTER TO GET IT at Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale…

Covering:
✅IMPASSION132💊
✅CAPITELLO291
✅PF-07220060
✅TROPION-BREAST01
✅BRCA BCY🤰
✅NATALEE
✅CARABELA
✅MORPHEUS-PAN BC
✅HER2DX🧬

account_circle
Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo

🙋🏻‍♀️ What a wonderful celebration for Felix Feng today — >200 scientists from all over the world celebrating his contributions to .
Thank you not enough to Felix Feng’s impact on our 🌎.
Thanks for organizing us Paul Nguyen Josh Lang

🙋🏻‍♀️ What a wonderful celebration for @felixfengmd today — >200 scientists from all over the world celebrating his contributions to #prostatecancer. Thank you not enough to @felixfengmd’s impact on our 🌎. Thanks for organizing us @DrPaulNguyen @JoshLangMD #UCSFBenioffInitiative
account_circle
Carlos Torrado(@CarlosTorradoMD) 's Twitter Profile Photo

Thrilled to be attending ASCO 2024 and honored to receive the Conquer Cancer Merit Award! Looking forward to connecting with outstanding professionals in Oncology.

Thrilled to be attending ASCO 2024 and honored to receive the Conquer Cancer Merit Award! Looking forward to connecting with outstanding professionals in Oncology. #ASCO2024 #CancerResearch #DrugDevelopment
account_circle
Tom Powles(@tompowles1) 's Twitter Profile Photo

Neoadjuvant chemo/nivo with adjuvant nivo show ⬆️ DFS (HR 0.58) & ⬆️pCR in NSCLC. 23% & 35% didn’t have surgery/adjuvant nivo respectively. Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durva/nivo/pembro) awaited.

Neoadjuvant chemo/nivo with adjuvant nivo show ⬆️ DFS (HR 0.58) & ⬆️pCR in NSCLC. 23% & 35% didn’t have surgery/adjuvant nivo respectively. Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durva/nivo/pembro) awaited.
account_circle